J Rheumatol:甲氨蝶呤治疗特发性肉芽肿性乳腺炎

2019-06-29 xiangting MedSci原创

甲氨蝶呤单药治疗是IGM的有效疗法。

特发性肉芽肿性乳腺炎(IGM)是一种影响外观的炎症性乳腺疾病,没有有效治疗方法。这里报道了一个使用甲氨蝶呤单药治疗的最大IGM队列。

对由风湿病诊所评估且组织病理学确诊的IGM患者进行病历回顾,这些患者使用甲氨蝶呤治疗,并且至少有一次随访预约。

确定了19名女性患者,平均年龄33.5岁。大多数患者抗生素、泼尼松和外科手术治疗失败。甲氨蝶呤治疗15个月后,94%的患者疾病改善,75%达到疾病缓解。

甲氨蝶呤单药治疗是IGM的有效疗法。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1894737, encodeId=48a71894e3764, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Jan 06 01:46:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344776, encodeId=0ab81344e76b7, content=<a href='/topic/show?id=0e98808e9f9' target=_blank style='color:#2F92EE;'>#肉芽肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80879, encryptionId=0e98808e9f9, topicName=肉芽肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Mon Jul 01 03:46:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418729, encodeId=6a761418e298e, content=<a href='/topic/show?id=e9f123e215e' target=_blank style='color:#2F92EE;'>#乳腺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23721, encryptionId=e9f123e215e, topicName=乳腺炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36963405262, createdName=andy2088, createdTime=Mon Jul 01 03:46:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1894737, encodeId=48a71894e3764, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Jan 06 01:46:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344776, encodeId=0ab81344e76b7, content=<a href='/topic/show?id=0e98808e9f9' target=_blank style='color:#2F92EE;'>#肉芽肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80879, encryptionId=0e98808e9f9, topicName=肉芽肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Mon Jul 01 03:46:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418729, encodeId=6a761418e298e, content=<a href='/topic/show?id=e9f123e215e' target=_blank style='color:#2F92EE;'>#乳腺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23721, encryptionId=e9f123e215e, topicName=乳腺炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36963405262, createdName=andy2088, createdTime=Mon Jul 01 03:46:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1894737, encodeId=48a71894e3764, content=<a href='/topic/show?id=e45b6e859f3' target=_blank style='color:#2F92EE;'>#特发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67859, encryptionId=e45b6e859f3, topicName=特发性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Mon Jan 06 01:46:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1344776, encodeId=0ab81344e76b7, content=<a href='/topic/show?id=0e98808e9f9' target=_blank style='color:#2F92EE;'>#肉芽肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80879, encryptionId=0e98808e9f9, topicName=肉芽肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=09a12500213, createdName=12498f1em08(暂无昵称), createdTime=Mon Jul 01 03:46:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1418729, encodeId=6a761418e298e, content=<a href='/topic/show?id=e9f123e215e' target=_blank style='color:#2F92EE;'>#乳腺炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23721, encryptionId=e9f123e215e, topicName=乳腺炎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36963405262, createdName=andy2088, createdTime=Mon Jul 01 03:46:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]

相关资讯

Lancet:Upadacitinib单药是否可替代甲氨蝶呤治疗类风湿性关节炎?

Upadacitinib,一种口服的JAK1选择性抑制剂,与稳定背景的传统合成疾病修饰抗风湿药物(csDMARDs)联合应用于对DMARDs不敏感的类风湿关节炎患者显示出疗效。现研究人员对Upadacitinib单药疗法替代甲氨蝶呤用于对甲氨蝶呤不敏感的患者的疗效和安全性进行评估。研究人员在24个国家的138个医疗点开展研究,招募年满18岁的类风湿性关节炎患者。将患者随机分至甲氨蝶呤治疗组、Upa

Ann Rheum Dis:甲氨蝶呤败下阵来 该派谁对抗“不死的癌症”RA?

对于类风湿关节炎(RA)患者,甲氨蝶呤一线治疗失败后,哪种改善病情抗风湿药(DMARD)方案效果更佳,尚是未知。2019年1月,荷兰、南非、苏格兰等国学者发表在《Ann Rheum Dis》的一项研究,对三种DMARD方案进行了比较。

Arthritis Rheumatol:依那西普和甲氨蝶呤单药或联合用药治疗银屑病关节炎的疗效

联合甲氨蝶呤和依那西普并未改善依那西普的疗效。

Ann Rheum Dis:早期使用TNF抑制剂有助于银屑病关节炎的缓解

在早期PsA患者中,第22周戈利木单抗+MTX的DAS缓解率几乎是单用MTX的2倍。

NEJM:低剂量甲氨蝶呤预防动脉粥样硬化事件

由此可见,在患有稳定的动脉粥样硬化的患者中,低剂量甲氨蝶呤没有降低白细胞介素-1β、白细胞介素-6或C-反应蛋白的水平,并且与安慰剂相比没有导致更少的心血管事件。

Lancet:Upadacitinib单药治疗甲氨蝶呤应答不充分的类风湿性关节炎

研究认为,Upadacitini单药治疗可显著患者甲氨蝶呤应答不充分的类风湿性关节炎患者疾病症状